Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-06-19
2000-01-11
Sisson, Bradley
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, A61K 3800, C07K 100
Patent
active
060136316
ABSTRACT:
Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5420019 (1995-05-01), Theofan et al.
patent: 5439807 (1995-08-01), Grinna et al.
patent: 5447913 (1995-09-01), Ammons et al.
patent: 5466580 (1995-11-01), White et al.
patent: 5466581 (1995-11-01), White et al.
patent: 5484705 (1996-01-01), White et al.
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494896 (1996-02-01), Hansbrough
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5532216 (1996-07-01), Espevik et al.
patent: 5576292 (1996-11-01), Elsbach et al.
patent: 5578568 (1996-11-01), Ammons et al.
patent: 5578572 (1996-11-01), Horwitz et al.
patent: 5627153 (1997-05-01), Little et al.
patent: 5639727 (1997-06-01), Little et al.
patent: 5641874 (1997-06-01), Elsbach et al.
patent: 5643570 (1997-07-01), Theofan et al.
patent: 5643875 (1997-07-01), Friedman et al.
patent: 5646114 (1997-07-01), Lambert
patent: 5652332 (1997-07-01), Little
patent: 5674834 (1997-10-01), Theofan et al.
patent: 5686414 (1997-11-01), Scannon
patent: 5696090 (1997-12-01), McGregor et al.
patent: 5703038 (1997-12-01), Ammons et al.
patent: 5731415 (1998-03-01), Gazzano-Santoro et al.
patent: 5733872 (1998-03-01), Little
patent: 5741779 (1998-04-01), White et al.
patent: 5753620 (1998-05-01), Friedmann et al.
patent: 5756464 (1998-05-01), Scannon et al.
patent: 5763567 (1998-06-01), Little, II
patent: 5770561 (1998-06-01), Horwitz et al.
patent: 5770694 (1998-06-01), Scott et al.
patent: 5783561 (1998-07-01), Horwitz et al.
patent: 5786324 (1998-07-01), Gray et al.
patent: 5804367 (1998-09-01), White et al.
patent: 5807818 (1998-09-01), Little, II
patent: 5821064 (1998-10-01), White et al.
patent: 5827816 (1998-10-01), Theofan et al.
patent: 5837678 (1998-11-01), Little, II
Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Endotoxemia and Gram-Negative Sepsis," in Novel Therapeutics Strategies in the Treatment of Sepsis, Morrison and Ryan, eds., Marcel Dekker, New York, pp. 55-70 (1996).
Beamer, L.J. et al., "Crystal Structure of Human BPI and Two Bound Phospholipids at 2.4 Angstrom Resolution," Science, 276:1861-1864 (Jun. 20, 1997).
Capodici, C. et al, "Both N- and C-Terminal Regions of the Bioactive N-Terminal Fragment of the Neutrophil Granule Bactericidal/Permeability-Increasing Protein Are Required for Stability and Function," J. Immunology, 156:4789-4796 (1996).
Dedrick, R.L. et al., "Elevated levels of lipopolysaccharide (LPS) binding protein (LBP) reduce the inflammatory potential of LPS in vitro and in vivo," CG 0356: Russ Dedrick; IES; Oct. 20-22, 1996; Nagoya, Japan.
Elsbach, P. et al., "Oxygen-Independent Antimicrobial Systems of Phagocytes", in Inflammation: Basic Principles and Clinical Correlates, Second Edition, eds. Gallin et al., Chapter 30, Raven Press, Ltd., New York (1992).
Elsbach, P. et al., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes," J. Biological Chemistry, 254:11000-11009 (1979).
Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," Infection and Immunity, 60:4754-4761 (1992).
Gray P.W. et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", J. Biologic Chemistry, 264(16):9505-9509 (Jun. 5, 1989).
Horwitz et al., "Expression and Characterization of Cysteine-Modified Variants of an Amino-Terminal Fragment of Bactericidal/Permeability-Increasing Protein," Protein Expression Purification, 8:28-40 (1996).
Horwitz, A.H. et al., "Human Lipopolysaccharide-Binding Protein Potentiates Bactericidal Activity of Human Bactericidal/Permeability-Increasing Protein," Infection and Immunity, 63(2):522-527 (Feb., 1995).
Int't Veld et al., "Effects of the Bactericidal/Permeability-Increasing Protein of Polymorphonuclear Leukocytes on Isolated Bacterial Cytoplasmic Membrane Vesicles", Infection and Immunity, 56(5):1203-1208 (May, 1988).
Mannion, B.A. et al., "Separation of Sublethal and Lethal Effects of the Bactericidal/Permeability Increasing Protein on Escherichia coli," J. Clinical Investigation, 85:853-860 (1990).
Mannion, B.A. et al., "Separation of Sublethal and Lethal Effects of Polymorphonuclear Leukocytes on Escherichia coli," J. Clinical Investigation, 86: 631-641 (1990).
Ooi, C.E. et al., "Endotoxin Neutralizing Properties of the 25 kD N-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., 174:649-655 (Sep., 1991).
Ooi, C.E. et al., "A 25-kDa NH.sub.2 -terminal Fragment Carries All the Antibacterial Activities of the Human Neutrophil 60-kDa Bactericidal/Permeability-increasing Protein," J. Biological Chemistry, 262:14891-14894 (1987).
Weiss, J. et al., "Resistance of Gram-negative Bacteria to Purified Bactericidal Leukocyte Proteins," J. Clinical Investigation, 65:619-628 (1980).
Weiss et al., "The Role of Lipopolysaccharide in the Action of the Bactericidal/Permeability Neutrophil Protein on the Bacterial Envelope", J. Immunol., 132:3109-3115 (Jun., 1984).
Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, 69(2):652-659 (1987).
Burke David
Carroll Stephen Fitzhugh
Horwitz Arnold
Sisson Bradley
Srivastava Devesh
Xoma Corporation
LandOfFree
Bactericidal/permeability-increasing protein (BPI) deletion anal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bactericidal/permeability-increasing protein (BPI) deletion anal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bactericidal/permeability-increasing protein (BPI) deletion anal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462450